Cystic fibrosis (CF) is an autosomal recessive, life-limiting, genetically inherited disease. It is a multi-system disorder and results from one of several identified...
Added 1 month ago Drug news
Vertex has announced that treatment with the triple combination of the next-generation corrector VX 445, tezacaftor and ivacaftor resulted in...
Added 2 months ago Drug news
Phase III study for tezacaftor/ivacaftor combination in cystic fibrosis supports European Medicines Agency submission.- Vertex
Vertex Pharmaceuticals Incorporated announced the results of a Phase III study conducted in Europe and Australia of tezacaftor in combination...
Added 3 months ago Drug news
European Commission approves Orkambi for the treatment of children with cystic fibrosis aged 2 to 5 years old who have two copies of the F508del mutation. - Vertex Pharma
Vertex Pharmaceuticals (Europe) Limited announced that the European Commission has granted approval of the label extension for Orkambi (lumacaftor/ivacaftor) for...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.
'New IBD assessment tools at a glance' - an educational symposium sponsored by Sandoz.
The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.
This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life.
Added 10 months ago
Specialised CF care has led to a dramatic improvement in survival in CF: in the last four decades, well above what was seen in the general population over the same period.
Added 4 years ago
Palliative care is an approach that improves quality of life for patients and their families facing problems associated with a life-threatening illness. Care planning is particularly important in CF...
Added 7 years ago
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.
Background: Ivacaftor is generally safe and effective in patients aged 2 years and older who have cystic fibrosis and specific CFTR mutations. We assessed its use in children aged 12 to <24 months.
Added 9 months ago
Ivacaftor restores CFTR-dependent sweat gland fluid secretion in cystic fibrosis subjects with S945L alleles.
Background: To determine in vivo effects of CFTR modulators on mutation S945L.
Added 1 year ago
- Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
- Credits available
- Registration required
- Subscription fee